Molecular analysis is very important in CLB‐AML with APL‐like phenotype in terms of predicting prognosis and determining the optimal treatment strategy including allogeneic stem cell transplantation or molecular targeted therapies such as FLT3 or IDH1/2 inhibitors. This evidence concerns the gene IDH1 and acute myeloid leukemia.